CTLA4 and neoplasm: For example, anti‐PD1/anti‐CTLA4 treatment can decrease pancreatic tumor growth by approximately 50%, while their combination with PLX3397 (CSF1R inhibitor) can dramatically attenuate tumor expansion and even results in tumor regression by 15%.51